 Phagoburn

Phagoburn was a European Union-financed phase I/II clinical study focused on testing the medical uses of bacteriophage for treating wounds that ran from 2013 to 2017.The main objective of Phagoburn was to assess the safety, effectiveness and pharmacodynamics of two therapeutic phage cocktails to treat "Escherichia coli" and "Pseudomonas aeruginosa" burn wound infections.